Edition:
United States

UCB SA (UCB.BR)

UCB.BR on Brussels Stock Exchange

70.44EUR
22 Jul 2016
Change (% chg)

€1.75 (+2.55%)
Prev Close
€68.69
Open
€68.44
Day's High
€70.46
Day's Low
€68.35
Volume
216,446
Avg. Vol
326,223
52-wk High
€86.05
52-wk Low
€61.60

UCB.BR

Chart for UCB.BR

About

UCB SA is a Belgium-based biopharmaceutical and specialty chemical company that specializes in two therapeutic areas: diseases of the central nervous system (CNS) and immunology. In the area of central nervous system disorders, the Company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia,... (more)

Overall

Beta: 0.50
Market Cap(Mil.): €13,700.98
Shares Outstanding(Mil.): 194.51
Dividend: 0.80
Yield (%): 1.14

Financials

  UCB.BR Industry Sector
P/E (TTM): 51.26 36.15 37.05
EPS (TTM): 1.37 -- --
ROI: 4.01 15.11 14.35
ROE: 4.95 16.17 15.56

BRIEF-Amgen and UCB submit biologics license application for romosozumab to the FDA

* Amgen and UCB submit biologics license application for romosozumab to the FDA

Jul 22 2016

REFILE-UCB receives approval for epilepsy drug Vimpat in Japan

July 4 Belgian pharmaceutical company UCB said on Monday it received regulatory approval for its epilepsy drug Vimpat in Japan.

Jul 04 2016

BRIEF-UCB's bimekizumab demonstrates positive results

* Says its bimekizumab demonstrates positive results in early development in patients with psoriatic arthritis Source text: http://bit.ly/1sy2B6M Further company coverage: (Gdynia Newsroom)

Jun 10 2016

BRIEF-UCB announces new clinical trial data on lacosamide

* Says new clinical trial data, presented at the second Congress of the European Academy of Neurology, showed non-inferiority of lacosamide (VIMPAT) monotherapy compared with controlled-release carbamazepine among patients with newly or recently diagnosed focal epilepsy Source text: http://bit.ly/1slGMaJ Further company coverage: (Gdynia Newsroom)

May 30 2016

UCB faces U.S. patent challenge for epilepsy drug

BRUSSELS The U.S. Patent and Trademark Office (PTO) is to review UCB's patent for its epilepsy drug Vimpat, the latest round in a legal battle between the Belgian pharmaceutical company and generic rivals.

May 24 2016

UCB faces U.S. patent challenge for epilepsy drug

BRUSSELS The U.S. Patent and Trademark Office (PTO) is to review UCB's patent for its epilepsy drug Vimpat, the latest round in a legal battle between the Belgian pharmaceutical company and generic rivals.

May 24 2016

UPDATE 1-UCB faces U.S. patent challenge for epilepsy drug

* U.S. court verdict on Vimpat likely in June (Adds shares, legal battle, analyst comment)

May 24 2016

UCB faces U.S. patent challenge for epilepsy drug

May 24 The U.S. Patent and Trademark Office (PTO) has begun a trial into whether Belgian pharmaceutical company UCB's patent for an epilepsy drug is valid, said a generic drug company that is challenging UCB's claim.

May 24 2016

BRIEF-UCB Q1 revenue rises to 991 million euros

* Q1 revenue 991 million euros versus 895 million euros year ago

Apr 25 2016

BRIEF-UCB announces results from study of Cimzia and Humira

* Announces results from first head-to-head study of Cimzia (certolizumab pegol) and Humira (adalimumab) in Bio-Naïve Rheumatoid Arthritis Patients

Mar 24 2016

Earnings vs. Estimates